Serum bFGF (Basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1189-1194

  Pichon, Marie France ^a   Moulin, G ^a   Pallud, C ^b   Pecking, A ^a   Floiras, J L ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b NONE

Author keywords

Basic fibroblast growth factor; Biological tumour marker; Breast cancer

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CA 15-3 ANTIGEN;

ADULT; ARTICLE; BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SERUM;

AGE FACTORS; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CA-15-3 ANTIGEN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MENOPAUSE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, STEROID; RECURRENCE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0034052292     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27-31, 1995
2. Weidner N, Semple JP, Welch WR and Folkman JO: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. New Engl J Med 324: 1-8, 1991.
3. Weidner N, Folkman J, Poza F, et al: Tumour angiogenesis: a new significant and independent pronostic indicator in early- stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
4. Toi M, Kashitani J and Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55: 371-374, 1993.
5. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M and Harris AL: Tumor angiogenesis in node - negative breast carcinomas - relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29: 109-116, 1994.
6. Dirix LY, Vermeulen PB. Pawinski A, et al: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76: 238-243, 1997.
7. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86: 356-361, 1994.
8. Kurobe M, Takei Y, Ezawa H, Hayashi K: Increased level of basic fibroblast growth factor (bFGF) in sera of patients with malignant tumours. Horm Metab Res 25: 395-396, 1993.
9. Hsu PI, Chow NH, Lai KH, et al: Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res 17: 2803-2809, 1997.
10. Dirix LY, Vermeulen PB, Hubens G et al: Serum basic growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 7: 843-848, 1996.
11. Colomer R, Aparicio J, Montero S, Guzman C, Larrodera L, Cortes-Funes H: Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 76: 1215-1220, 1997.
12. Relf M, LeJeune S, Scott PAE et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor ß-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963-96, 1997.
13. Linder C, Bystrom G, Engel G et al: Correlation between basic fibroblast growth factor immunostaining of stromal cells and stromelysin-3 mRNA expression in human breast carcinoma. Br J Cancer 77: 941-945, 1998.
14. Anandappa SY, Winstanley JHR, Leinster S, Green B, Rudland PS, Barraclough R: Comparative expression of fibroblast growth factor mRNA in benign and malignant breast disease. Br J Cancer 69: 772-776, 1994.
15. Yiangou C, Gomm JJ, Coope RC et al: Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Cancer Res 75: 28-33, 1997.
16. Ralph Anderson A: Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristics curve analysis. Ann Clin Biochem 30: 521-539, 1993.
17. Takei Y, Kurobe M, Uchida A, Hayashi K: Serum concentration of basic fibroblast growth factor in breast cancer. Clin Chem 40: 1980-198, 1994.
18. Sliutz G, Tempfer C, Obermair A, Dadak CH, Kainz CH: Serum evaluation of basic FGF in breast cancer patients. Anticancer Res 15: 2675-2678, 1995.
19. Hayes DF: Angiogenesis and breast cancer. Hematol Oncol Clin North Am 8: 51-71, 1994.
20. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-354, 1996.
21. Lee AHS, Happerfield LC, Bobrow LG and Millis R: Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol 181: 200-206, 1997.
22. Cuevas P, Barrios V, Gimenez-Gallego G, et al: Serum levels of basic fibroblast growth factor in acute myocardial infarction. Eur J Med Res 2: 282-284, 1997.
23. Jin-No K, Tanimizu M, Hyodo 1, Kurimoto F, Yamashita T: Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J Gastroenterol 32: 119-121, 1997.